Cargando…

Paradoxical Reaction in a Patient with Hidradenitis Suppurativa Undergoing Adalimumab Treatment

Detalles Bibliográficos
Autores principales:	IKEYA, Soichiro, TAKEICHI, Takuya, TAKI, Tomoki, MURO, Yoshinao, OGI, Tomoo, AKIYAMA, Masashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Publication of Acta Dermato-Venereologica 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380276/ https://www.ncbi.nlm.nih.gov/pubmed/34043022 http://dx.doi.org/10.2340/00015555-3844

Ejemplares similares

Two Cases of Paradoxical Hidradenitis Suppurativa while on Adalimumab
por: Harvin, Glenn, et al.
Publicado: (2016)

Two Cases of Porokeratosis with MVD Mutations, in Association with Bullous Pemphigoid
por: ARISAWA, Yuki, et al.
Publicado: (2021)

Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real‐life experience and therapeutic response to other biological drugs
por: Burzi, Lorenza, et al.
Publicado: (2022)

Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn’s Disease?
por: Beraldo, Rodrigo Fedatto, et al.
Publicado: (2020)

Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab
por: Gorovoy, Ian, et al.
Publicado: (2009)

Hidradenitis suppurativa and adalimumab in the COVID-19 era
por: Marzano, Angelo Valerio, et al.
Publicado: (2021)

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

Deep Phenotyping of Superficial Epidermolytic Ichthyosis due to a Recurrent Mutation in KRT2
por: Suzuki, Yuika, et al.
Publicado: (2022)

Treatment of Hidradenitis Suppurativa Patient with Klinefelter Syndrome by Adalimumab
por: Shin, Ji Yeoun, et al.
Publicado: (2019)

Adalimumab-Induced Thrombocytopenia in a Patient With Hidradenitis Suppurativa
por: Al-Tkrit, Amna, et al.
Publicado: (2021)

ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa
por: Craig, Alexander, et al.
Publicado: (2023)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis
por: Ryan, Caitriona, et al.
Publicado: (2018)

Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa
por: Fotiadou, Christina, et al.
Publicado: (2016)

Genital lymphedema associated with hidradenitis suppurativa unresponsive to adalimumab treatment
por: Musumeci, Maria Letizia, et al.
Publicado: (2019)

A complication in a patient with hidradenitis suppurativa taking adalimumab
por: Perez, Olivia D., et al.
Publicado: (2022)

Optic neuropathy in a patient treated with adalimumab for hidradenitis suppurativa
por: Alnaif, Sarah, et al.
Publicado: (2023)

Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab
por: Bosnić, Dubravka, et al.
Publicado: (2016)

Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data
por: Kyriakou, Aikaterini, et al.
Publicado: (2018)

The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa
por: Frew, John W., et al.
Publicado: (2021)

Real-world drug survival of patients with hidradenitis suppurativa treated with adalimumab
por: Saal, Ryan C., et al.
Publicado: (2023)

Impact of Bariatric Surgery on Hidradenitis Suppurativa
por: CANARD, Clothilde, et al.
Publicado: (2021)

Hidradenitis Suppurativa Prevalence in Nuuk, Greenland: Physician Validation of a Hidradenitis Suppurativa Questionnaire in a Greenlandic Setting
por: BOTVID, Sofia H. C., et al.
Publicado: (2023)

Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study
por: REPETTO, Federica, et al.
Publicado: (2023)

HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study
por: Kimball, A.B., et al.
Publicado: (2015)

Odontogenic keratocysts are an important clue for diagnosing basal cell nevus syndrome
por: Kaibuchi-Ando, Kaori, et al.
Publicado: (2021)

Metastatic squamous cell carcinoma in a patient treated with adalimumab for hidradenitis suppurativa
por: Giesey, Rachel, et al.
Publicado: (2017)

Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic
por: Kearns, Donovan G., et al.
Publicado: (2020)

Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis
por: Alam, Maryam Shayesteh, et al.
Publicado: (2020)

Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations
por: Blaszczak, Alecia, et al.
Publicado: (2020)

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
por: Montero-Vilchez, Trinidad, et al.
Publicado: (2022)

Adalimumab Effect on Pain in Hidradenitis Suppurativa Patients: Systematic Review and Meta-Analysis
por: Tsentemeidou, Aikaterini, et al.
Publicado: (2022)

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
por: Burlando, Martina, et al.
Publicado: (2022)

Adalimumab for the Treatment of Periodontitis in a 35-Year-Old Woman with Hidradenitis Suppurativa
por: Yao, Yiqiu, et al.
Publicado: (2023)

Should Patients with Hidradenitis Suppurativa Undergo LASIK?
por: Rosen, David B., et al.
Publicado: (2019)

Effect of Hidradenitis Suppurativa Disease Duration on Psychiatric Comorbidity
por: TIRI, Hannu, et al.
Publicado: (2020)

Hidradenitis suppurativa with SAPHO syndrome maintained effectively with adalimumab, methotrexate, and intralesional corticosteroid injections
por: Crowley, Erika L, et al.
Publicado: (2018)

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study
por: Prens, L.M., et al.
Publicado: (2021)

Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa
por: Tatian, Artiene, et al.
Publicado: (2022)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
por: Martora, Fabrizio, et al.
Publicado: (2023)

Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study
por: Vossen, Allard R. J. V., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_a2qsr9lu4bmbdtmmcnjn4mna5h